Home › Conditions › Major Haemorrhage on Anticoagulation
Haematology
Major Haemorrhage on Anticoagulation
Life-threatening bleeding on anticoagulation requires immediate reversal using agent-specific antidotes. The major haemorrhage protocol (MHP) should be activated for haemodynamically significant bleeding. Restart timing depends on the bleeding site and control, anticoagulant and thrombotic risk. GI bleeding does not routinely require a 4–8-week delay.
BSH/NICE Anticoagulant Reversal Protocol
The pathway
Activate major haemorrhage protocol
- Activate MHP early for ongoing life-threatening bleeding with shock or rapidly escalating transfusion needs; do not wait for a fixed unit count
- SBP <90 with bleeding is a warning sign; assess perfusion and response to resuscitation
- Critical-site bleeding (e.g. intracranial, spinal, pericardial): urgent reversal and specialist review; activate MHP if major blood loss/circulatory compromise also warrants it
- Notify haematology, blood bank, and senior clinical team
- Send: FBC, PT/INR, APTT, fibrinogen, group & save/crossmatch, anti-Xa level (for LMWH/DOAC)
Warfarin reversal
- INR >8 without bleeding: Vitamin K 1–2mg PO or 0.5–1mg IV
- INR >8 with minor bleeding: Vitamin K 3mg IV + consider PCC
- Any bleeding with haemodynamic instability: Vitamin K 5–10mg IV + 4-factor PCC (Beriplex/Octaplex) 25–50 IU/kg
- PCC works within minutes; Vitamin K takes 6–12 hours
Dabigatran reversal
- Idarucizumab (Praxbind) 5g IV as two sequential 2.5g doses over 5–10 minutes each (or as consecutive IV bolus injections)
- Specific antidote to dabigatran — reverses within minutes
- Use for life-threatening or uncontrolled bleeding, or emergency surgery/urgent procedures requiring rapid reversal
- Check thrombin time (TT) or dilute TT to guide; APTT less reliable
Rivaroxaban / Apixaban reversal; edoxaban needs specialist advice
- Andexanet alfa (Ondexxya): licensed for life-threatening/uncontrolled bleeding on apixaban or rivaroxaban
- High-dose: 800mg IV bolus then 8mg/min for 120 minutes (rivaroxaban >10mg or apixaban >5mg taken <8h ago)
- Low-dose: 400mg IV bolus then 4mg/min for 120 minutes (apixaban ≤5mg, rivaroxaban ≤10mg, or last dose ≥8h ago)
- If andexanet alfa unavailable: 4-factor PCC 50 IU/kg as alternative
- Check anti-Xa level (drug-specific assay)
- Unknown dose/timing: specialist advice; UK SmPC gives no dose recommendation
- Edoxaban: no licensed andexanet regimen; urgent haematology advice
LMWH reversal
- Protamine sulphate: neutralises unfractionated heparin completely, LMWH partially
- Stop UFH. Protamine up to 1mg/100 units; reduce for elapsed time since IV bolus, with haematology/pharmacy
- Maximum 50mg per dose, IV over 10 minutes; recheck APTT after 5–15 minutes for UFH reversal
- For LMWH: if within 8 hours: 1mg protamine per 1mg enoxaparin; partial reversal only (maximum about 60% of enoxaparin anti-Xa activity)
- Enoxaparin >8h ago: 0.5mg protamine per 1mg enoxaparin; after 12h, it may not be needed. Discuss persistent bleeding/accumulation with haematology
- Warn of risk of anaphylaxis (fish allergy, previous protamine exposure)
Supportive haemostatic measures
- Major trauma with bleeding: TXA 1g IV over 10 minutes, then 1g over 8h; start as soon as possible within 3h of injury
- Head injury, age ≥16, GCS ≤12, no suspected active extracranial bleeding: consider TXA 2g IV bolus within 2h, before imaging
- Surgical haemorrhage: TXA 1g IV over 10 minutes; discuss with the surgical/anaesthetic team
- FFP 15 mL/kg for factor deficiency in major haemorrhage. Does not reverse DOACs.
- Cryoprecipitate if fibrinogen <1.5g/L
- Active major bleeding/shock: transfuse to clinical response (MHP). Once controlled: transfuse at Hb <70, target 70–90 g/L; ACS <80, target 80–100 g/L.
- Platelet transfusion if <50 × 10⁹/L with bleeding
Anticoagulation restart decision
- Once bleeding is controlled, agree a documented restart/review date with the relevant specialist
- GI bleed: plan restart around 7 days; earlier if thrombotic risk warrants. DOACs act rapidly
- Intracranial bleed: a separate neurology/haematology decision; do not apply GI timing
- Mechanical heart valves: discuss urgently with cardiothoracic team — early bridging may be needed
- VTE within 3 months: high thrombotic risk — consider IVC filter as bridge
- Decision documented with patient + multidisciplinary team
Drugs
| Drug | Dose | Route | Notes |
|---|---|---|---|
| 4-factor PCC (Beriplex / Octaplex) | 25–50 IU/kg | IV | Warfarin/VKA reversal, or when a specific DOAC antidote is unavailable. Works within minutes. Give vitamin K alongside it for VKA reversal only — vitamin K does nothing for a DOAC. Repeat dosing is not recommended (Beriplex SmPC: not supported by clinical data). |
| Vitamin K (phytomenadione) | 5–10mg | IV | For warfarin/VKA reversal only — not for DOAC bleeding. Co-administer with PCC; takes 6–12h to work, so PCC provides the immediate cover. IV preferred over oral in major bleeding. |
| Idarucizumab (Praxbind) | 5g (as 2 × 2.5g doses) | IV | - Specific dabigatran antidote - Give two consecutive 2.5g IV doses, each over 5–10 minutes, or as bolus injections - Rapid reversal; monitor bleeding and dabigatran-sensitive clotting tests |
| Andexanet alfa (Ondexxya) | 400–800mg bolus then 4–8mg/min for 120 min | IV | Factor Xa inhibitor antidote (rivaroxaban, apixaban). Dose depends on DOAC dose and timing. Specialist pharmacy involvement required. Obtain any drug-specific anti-Xa sample before treatment if it will help without delaying reversal. After andexanet, monitor haemostasis, rebleeding and thrombosis clinically; routine anti-Xa assays are unreliable. |
| Protamine sulphate | Up to 1mg per 100 units UFH; adjust for timing (max 50mg per dose) | IV slow | - Stop heparin; confirm dose, route and timing with haematology/pharmacy - Give over 10 minutes; for UFH, recheck APTT after 5–15 minutes - Anaphylaxis risk: resuscitation equipment at bedside - LMWH reversal is partial; use the enoxaparin regimen above |
| Tranexamic acid | Major trauma: 1g over 10 minutes, then 1g over 8h; selected head injury: 2g bolus | IV | Adjunct for traumatic or surgical haemorrhage. AVOID in haematuria (risk of clot retention) and subarachnoid haemorrhage without trauma. - Head injury: age ≥16, GCS ≤12, no suspected active extracranial bleeding: consider 2g IV within 2h, before imaging - Major trauma with bleeding: start within 3h; later only if hyperfibrinolysis is demonstrated - TXA does not replace anticoagulant reversal; check any pre-hospital dose |
When to escalate
- Intracranial haemorrhage — immediate neurosurgical and haematology review, reverse within 30 minutes
- SBP <90 despite initial resuscitation — activate MHP, ITU referral
- Ongoing haemorrhage despite reversal agent — surgical/interventional radiology
- Dabigatran toxicity with renal failure — consider haemodialysis (dabigatran is dialysable)
- Mechanical heart valve patient with major bleed — urgent cardiothoracic input for bridging strategy
- INR not correcting after PCC — haematology now. Check fibrinogen and for DIC; repeat PCC dosing is NOT routinely recommended
Reference: BSH Guideline on the Use of Anticoagulant Reversal Agents 2022 / NICE NG196
Practise and explore
Practise a case or explore differentials here on the website. The optional browser app adds personal learning tools and saved progress.